Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay

  • News

Executive Summary

Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented

You may also be interested in...



Rx Imports: Pfizer Says Political Bark Is Worse Than Commercial Bite

The impact of Canadian imports on Pfizer's U.S. pharmaceutical business represents less than two-tenths of one percent of sales, the company indicated during an Oct. 22 conference call

Rx Imports: Pfizer Says Political Bark Is Worse Than Commercial Bite

The impact of Canadian imports on Pfizer's U.S. pharmaceutical business represents less than two-tenths of one percent of sales, the company indicated during an Oct. 22 conference call

Reimportation In North America Is Inevitable, Roche Suggests; EU Is Model

A U.S./Canada pharmaceutical importation system may be inevitable, Roche Global Pharmaceutical Head William Burns suggested during an Oct. 16 investor conference call

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By